NCT06451497 2024-12-04Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid TumorsZumutor Biologics Inc.Phase 1 Recruiting33 enrolled
NCT05259397 2023-03-08PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)PfizerPhase 1 Withdrawn